These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32940168)

  • 1. Diabetic Theory in Anti-Alzheimer's Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors.
    Jankowska A; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2021; 28(18):3535-3553. PubMed ID: 32940168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.
    Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2020; 27(39):6658-6681. PubMed ID: 31604406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease.
    Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
    Curr Med Chem; 2020; 27(32):5351-5373. PubMed ID: 31250747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR; Wouters C; Prickaerts J
    Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
    Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
    Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?
    Ghavami A; Hirst WD; Novak TJ
    Drugs R D; 2006; 7(2):63-71. PubMed ID: 16542053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors.
    Sallustio F; Studer V
    CNS Neurol Disord Drug Targets; 2016; 15(6):647-59. PubMed ID: 27189469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases.
    Chen Y; Wang H; Wang WZ; Wang D; Skaggs K; Zhang HT
    Neuropharmacology; 2021 Sep; 196():108694. PubMed ID: 34245775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases.
    Martinez A; Gil C
    Expert Opin Ther Pat; 2014 Dec; 24(12):1311-21. PubMed ID: 25284693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research.
    Jankowska A; Swierczek A; Chlon-Rzepa G; Pawlowski M; Wyska E
    Curr Med Chem; 2017; 24(7):673-700. PubMed ID: 28093982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE and cognitive processing: beyond the memory domain.
    Heckman PR; Blokland A; Ramaekers J; Prickaerts J
    Neurobiol Learn Mem; 2015 Mar; 119():108-22. PubMed ID: 25464010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition.
    Bartolome F; de la Cueva M; Pascual C; Antequera D; Fernandez T; Gil C; Martinez A; Carro E
    Alzheimers Res Ther; 2018 Feb; 10(1):24. PubMed ID: 29458418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease.
    Perez-Gonzalez R; Pascual C; Antequera D; Bolos M; Redondo M; Perez DI; Pérez-Grijalba V; Krzyzanowska A; Sarasa M; Gil C; Ferrer I; Martinez A; Carro E
    Neurobiol Aging; 2013 Sep; 34(9):2133-45. PubMed ID: 23582662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.